Equities

Soligenix Inc

Soligenix Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.06
  • Today's Change-0.09 / -2.17%
  • Shares traded472.17k
  • 1 Year change-65.62%
  • Beta1.9326
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.

  • Revenue in USD (TTM)699.21k
  • Net income in USD-7.01m
  • Incorporated1987
  • Employees13.00
  • Location
    Soligenix IncSUITE C-10, 29 EMMONS DRIVEPRINCETON 08540United StatesUSA
  • Phone+1 (609) 538-8200
  • Fax+1 (609) 452-6467
  • Websitehttps://www.soligenix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
NS Wind Down Co Inc162.47m-166.43m3.76m703.00------0.0231-3.53-3.533.44-1.050.49362.074.30231,113.80-50.56-30.01-62.82-34.6635.7257.14-102.44-80.872.02-70.171.29---12.282.06-38.43--40.03--
4Cable TV International Inc758.68k-3.14m3.81m0.00------5.03-0.0624-0.06240.0157-0.04121.071.8425.22---441.73-82.30---308.1029.92---414.41-47.620.0064-0.5271-----0.0914---731.54------
Phio Pharmaceuticals Corp0.00-9.38m3.88m8.00--0.5822-----3.71-3.710.001.220.00----0.00-113.26-71.92-145.23-84.15-------253,785.70----0.00------5.70--0.00--
ProtoKinetix, Inc.0.00-400.47k3.92m0.00--9.88-----0.0012-0.00120.000.00110.00-------88.14-696.88-101.62-785.51------------0.00------78.22--10.78--
Ensysce Biosciences Inc1.75m-11.55m3.94m7.00--1.02--2.26-3.74-3.740.51090.51150.3886--9.06249,514.30-257.00-17.68-574.02-19.42-----661.34-715.78---6.250.0671---11.61--57.64------
Mosaic Immunoengineering Inc0.00-897.69k3.98m3.00---------0.1245-0.12450.00-0.84980.00----0.00-789.46-----------------26.91--------57.65------
Soligenix Inc699.21k-7.01m4.01m13.00--3.48--5.73-11.83-11.831.161.170.073--4.1753,785.38-73.17-75.40-2,448.34-154.329.4622.83-1,002.55-620.02----0.7959---11.54-30.6755.50------
Neximmune Inc0.00-25.86m4.04m6.00--1.47-----24.16-24.160.002.160.00----0.00-130.41-115.07-183.16-165.07------------0.00------48.25---44.65--
Silo Pharma Inc72.12k-3.53m4.06m3.00--0.589--56.23-1.18-1.200.0241.870.008----24,040.00-39.26-24.90-43.11-26.3991.9082.79-4,889.57-2,757.85----0.00--0.00--7.07------
Evoke Pharma Inc6.11m-7.13m4.06m4.00--1.16--0.6645-1.83-1.831.280.40680.54290.51135.711,526,428.00-63.39-100.48-76.67-151.1096.01---116.76-480.525.35-19.250.5884--106.51--5.25------
GB Sciences Inc0.00-4.03m4.06m3.00---------0.0105-0.01050.00-0.01190.00----0.00-255.86-49.16---131.40--6.03---995.19---8.63---------2,715.25---60.82--
China Pharma Holdings Inc6.42m-3.56m4.09m231.00--0.4608--0.6374-0.8352-0.83521.030.55960.38281.9314.1427,795.89-21.22-29.66-44.77-55.25-11.676.47-55.42-73.090.2523-11.340.261---13.48-10.6822.50---25.78--
Cingulate Inc0.00-22.50m4.12m13.00--1.03-----22.66-22.660.000.64190.00----0.00-355.56---1,198.96-------------33.880.0054-------33.14------
Reliv International Inc35.13m-175.48k4.23m208.00--0.61110.590.1205-0.1005-0.100520.126.552.098.02228.49---1.05-4.65-1.47-6.0640.9041.98-0.4996-2.331.07--0.1064---2.94-9.3776.65---35.85--
Virax Biolabs Group Ltd0.00-1.71m4.28m5.00---------1.50-1.500.00-0.8568------0.00----------------0.0223-112.29-----100.00---162.50------
Azitra Inc572.70k-12.40m4.30m10.00--0.9945--7.51-2.87-2.870.04920.15010.0977--11.5457,270.00-200.61---287.43-------2,053.34-----129.020.0085--141.55--6.02------
Data as of Jun 14 2024. Currency figures normalised to Soligenix Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.